Metformin may lower colorectal cancer risk by stopping precancerous lesion formation
the ONA take:
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.
Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.
Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.
Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.
“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|